Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating Neurodegenerative Diseases as Metabolic Diseases
136,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
68 °P sammeln
  • Gebundenes Buch

Metabolic Drivers and Bioenergetic Components of Neurodegenerative Disease reviews how the different aspects of metabolic dysfunction and consequent pathology associated with neurodegenerative diseases, including Alzheimer's and Parkinson's, can be targeted by novel treatment approaches. Topics covered include Cellular Senescence in Aging and Age-Related Disorders: Implications for Neurodegenerative Diseases; Repurposing GLP1 agonists for Neurodegenerative Diseases; Ketotherapeutics for Neurodegenerative Diseases; Enhancing Mitophagy as a Therapeutic Approach for Neurodegenerative Diseases;…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Metabolic Drivers and Bioenergetic Components of Neurodegenerative Disease reviews how the different aspects of metabolic dysfunction and consequent pathology associated with neurodegenerative diseases, including Alzheimer's and Parkinson's, can be targeted by novel treatment approaches. Topics covered include Cellular Senescence in Aging and Age-Related Disorders: Implications for Neurodegenerative Diseases; Repurposing GLP1 agonists for Neurodegenerative Diseases; Ketotherapeutics for Neurodegenerative Diseases; Enhancing Mitophagy as a Therapeutic Approach for Neurodegenerative Diseases; Harnessing Neurogenesis in the Adult Brain - A Role in Type 2 Diabetes Mellitus and Alzheimer's disease; and much more.
Autorenporträt
Grazyna Söderbom, PhD is founder of Klipspringer AB. She received her BSc 1st Class Hons in Pharmacology & Toxicology from King's College, London and PhD in Neuroscience from the University of London. She spent one year of her undergraduate studies investigating the role of the AT2-receptor subtype at Ciba-Geigy under the tutelage of Dr Marc de Gasparo. As a Wellcome Trust PhD Scholar in Prof. Peter Jenner's Neurodegenerative Research Group, Grazyna focused on the aetiology of Parkinson's disease, specifically the relevance of antioxidant enzymes in the basal ganglia and Parkinson's pathogenesis. After working as a Post-Doctoral Research Fellow at the Clinical Age Research Unit at King's College Hospital, Grazyna joined Zeneca/AstraZeneca Pharmaceuticals, which included five years as Global Brand Manager in Cardiovascular Medicine in Sweden. She was involved in the global marketing and communications behind the antihypertensive Atacand® and the launch of Atacand Plus®. Having disc

overed a strong interest in strategic medical communications, Grazyna launched Klipspringer in 2013, which specializes in scientific, medical and strategic writing and consultation for Academia, Bio-Pharma and beyond. Grazyna is passionate about "all things science?, especially neuroscience, and the effective sharing of scientific knowledge to all levels of audiences. She has published scientific research of her own and now supports others in their scientific and medical communications. Grazyna is particularly interested in the potential implications of the link between metabolic disease and neurodegenerative disorders.